⌘K
t
On 07 April 2026, Cambridge Cognition Holdings plc appointed Cavendish Capital Markets Limited as its Nominated Adviser and Joint Broker with immediate effect. Singer Capital Markets Limited remains in its role as Joint Corporate Broker. The company also disclosed that Chairman Steven Powell was a director of Ribonexus SAS, which entered court-ordered liquidation in April 2024, and that Powell resigned from LCC Therapeutics on 17 June 2025, prior to its creditors voluntary liquidation on 16 October 2025.
| Date | 7 Apr 2026 |
| Time | 07:00:11 |
| Category | Corporate updates |
| ID | 3410Z |
7 April 2026
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Appointment of Nominated Adviser and Joint Broker
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces the appointment of Cavendish Capital Markets Limited as the Company's Nominated Adviser and Joint Broker with immediate effect.
Singer Capital Markets remain in their role as Joint Corporate Broker.
Enquiries:
|
Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer
|
Tel: 01223 810700 |
|
Cavendish Capital Markets Limited (NOMAD and Joint Broker) Geoff Nash / Elysia Bough / Joe Smith Harriet Ward Nigel Birks
|
Tel: 020 7220 0500 Corporate Finance Corporate Broking LS Specialist Sales |
|
Singer Capital Markets Limited (Joint Broker) Amber Higgs / James Serjeant / Daniel Ingram |
Tel: 020 7496 3000
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care.
Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts. The Company has identified four market sectors:
For further information, visit: www.cambridgecognition.com
Existing Board - AIM Rule 17 Disclosure
The Company confirms the following director disclosures pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.
Steven Powell (Chairman)
Ribonexus SAS, a company which Steven Powell is a director of, entered into a court-ordered liquidation in April 2024. The Company is currently still in liquidation.
Steven was previously a director of LCC Therapeutics, resigning on 17 June 2025. After he had left employment, the company appointed an administrator and later entered into a creditors voluntary liquidation on 16 October 2025. The Company is currently still in liquidation.